Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcript
Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcript
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates
Merck (MRK) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $2.13 per share a year ago.
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line
Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity
Merck & Co., Inc. NYSE: MRK outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate.
Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
Merck has extended Keytruda's lifecycle by launching subcutaneous Qlex, securing its exclusivity through 2039, and other extensions supporting market confidence. Recent regulatory approvals, promising pipeline updates, and two major acquisitions (Terns, Cidara) have broadened MRK's oncology and virology portfolios. Analyst long-term EPS estimates have improved, but the stock's 17% rally since the latest quarterly results and 2030–32 P/E of ~13.5 suggest the current valuation is fully justified.
Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
Merck MRK is set to report its second-quarter 2026 earnings on Aug. 4, before market open. The Zacks Consensus Estimate for second-quarter sales is pegged at $16.33 billion, while the same for earnings stands at a loss of 26 cents per share.
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
Hilleman Laboratories, a Singapore-based joint venture between Merck and the global charity Wellcome, is gearing up to manufacture doses of a promising experimental vaccine against the rare Bundibugyo strain of Ebola responsible for a fast-spreading outbreak in the Democratic Republic of Congo.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
